Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.
Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly
Aspen’s Stephen Saad and Sean Capazorio will take part in Investec’s CEO conference in London
Aspen has contributed towards the funding of a new mobile cancer screening clinic for rural
JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid
Durban – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded
Johannesburg, South Africa – Aspen Pharmacare Holdings Limited (“Aspen”), a global multinational specialty pharmaceutical company,
Durban, South Africa – JSE-listed Aspen Pharmacare Holdings Limited, a global multinational specialty pharmaceutical company, has announced that Aspen Global Incorporated (“AGI”), its wholly owned
Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility Durban, South Africa
Subject to approval from relevant Competition Authorities, Lilly will enter a strategic agreement with Aspen to continue serving patients and bring innovative therapies to South
Dubai, United Arab Emirates – Aspen Healthcare FZ LLC (“Aspen Healthcare”), a subsidiary of Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded multinational
New funding supports technology transfer from Serum Institute to Aspen to manufacture routine vaccines in Africa, for Africa Collaboration supports sustainable manufacturing capacity for African-produced
Durban, South Africa – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to announce that one of its wholly-owned South
Durban – JSE listed company Aspen Pharmacare Holdings Limited (Aspen), a global multinational specialty pharmaceutical company, is positively positioned to respond as a third party
“With the conclusion of this agreement, our vision for Africa’s own vaccine has become a reality,” said Stephen Saad, Aspen Group Chief Executive.
Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912
Medical Careline (South Africa) 0800 118 088
ASPEN PHARMACARE HOLDINGS LTD:
Switchboard: +27 31 580-8600
Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
South Africa
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com